Browse LPA

Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00051 Kringle domain
PF00089 Trypsin
Function

Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330.

> Gene Ontology
 
Biological Process GO:0003013 circulatory system process
GO:0006869 lipid transport
GO:0008015 blood circulation
GO:0010466 negative regulation of peptidase activity
GO:0010876 lipid localization
GO:0010951 negative regulation of endopeptidase activity
GO:0042157 lipoprotein metabolic process
GO:0045861 negative regulation of proteolysis
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
Molecular Function GO:0001968 fibronectin binding
GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
GO:0030414 peptidase inhibitor activity
GO:0034185 apolipoprotein binding
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
GO:1901681 sulfur compound binding
Cellular Component GO:0032994 protein-lipid complex
GO:0034358 plasma lipoprotein particle
GO:1990777 lipoprotein particle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-171052: LDL-mediated lipid transport
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LPA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LPA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LPA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2580.338
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0030.996
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4540.38
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4720.441
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4730.791
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4850.794
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4270.651
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7340.7
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0920.961
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0040.996
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4140.642
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.9760.033
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LPA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.512.36.20.518
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.515.33.20.757
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.65.922.70.104
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.89.121.70.327
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LPA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LPA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LPA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LPA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LPA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LPA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLPA
Namelipoprotein, Lp(a)
Aliases AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a)
Chromosomal Location6q25-q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LPA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LPA.
ID Name Drug Type Targets #Targets
DB00513Aminocaproic AcidSmall MoleculeLPA, PLAT, PLG3